Yokneam, Israel (PRWEB) July 31, 2014
Qutromtech's progress in the development of biological medicine coincided with the decline of existing chemical molecules based drugs, after suffering during the last two decades competition from generic companies, including Qutromtech. However, generic competition to biological drugs is seen in the near future due to the extremely complex development processes, in addition to patent protection of the new drugs.
Thus, the field of biotechnology appears as the main growth engine of the pharmaceutical industry at large, and this leads to increased interest in the biotech sector, both from large pharmaceutical companies as well as investors.
In light of these factors, Qutromtech introduced particularly strong performance last year and early this year, it has positive return of tens of percents in the shares of leading companies, and hundreds of percents among small companies that are of higher risk level.